Not available
Quote | Axsome Therapeutics Inc. (NASDAQ:AXSM)
Last: | $82.02 |
---|---|
Change Percent: | 0.32% |
Open: | $79.95 |
Close: | $82.02 |
High: | $82.105 |
Low: | $79.725 |
Volume: | 810,446 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Axsome Therapeutics Inc. (NASDAQ:AXSM)
2024-07-04 10:01:38 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the critical components of the investing world is the proliferation and understanding of analyst predictions. That’s because most retail investors prefer to research consumer info...
2024-07-03 13:34:14 ET Mizhuo picks Axsome Therapeutics ( AXSM ), Wave Life Sciences ( WVE ), Arcutis Biotherapeutics ( ARQT ), LivaNova ( LIVN ) and Humana ( HUM ) as July’s top picks.... Read the full article on Seeking Alpha For further details see:...
Message Board Posts | Axsome Therapeutics Inc. (NASDAQ:AXSM)
Subject | By | Source | When |
---|---|---|---|
$AXSM Price now last trade up | Frankestin | investorshub | 06/27/2023 11:05:09 PM |
$AXSM best news of the day | MiamiGent | investorshub | 06/26/2023 5:43:47 AM |
New mid term topic $100.00 by or before | georgejjl | investorshub | 06/23/2023 4:29:46 PM |
$AXSM what do you make of this data? | georgejjl | investorshub | 06/23/2023 3:51:48 PM |
Their target has been reached. Now what? | rosemountbomber | investorshub | 06/23/2023 12:11:48 PM |
News, Short Squeeze, Breakout and More Instantly...
Axsome Therapeutics Inc. Company Name:
AXSM Stock Symbol:
NASDAQ Market:
Axsome Therapeutics Inc. Website:
2024-06-27 09:42:00 ET There are things that can affect and sink the stock prices of companies in most industries. One of them is a short-seller report. Axsome Therapeutics (NASDAQ: AXSM) , a mid-cap biotech, was recently the target of one, and it already wasn't having a great year ...
2024-06-11 16:30:03 ET Guggenheim analyst issues BUY recommendation for AXSM on June 11, 2024 03:28PM ET. The previous analyst recommendation was Buy. AXSM was trading at $71.07 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current anal...